Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
Status:
Withdrawn
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
This multicenter, randomized, open-label study will assess the safety and efficacy of oral
treprostinil in subjects diagnosed with pulmonary hypertension associated with pulmonary
fibrosis.